Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2354-2364
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2354
Table 1 Baseline characteristics of the 40 patients with Crohn’s disease included in this study
n = 40 patients
Age at the time of inclusion, mean ± SD (yr)34 .0 ± 13.6
Disease duration, median (IQR) (yr)4 (0.8-11.3)
Female gender, n (%)21 (52.5)
Current smokers, n (%)15 (37.5)
Prior bowel resection, n (%)7 (17.5)
Montreal classification
Location
L1, n (%)18 (45.0)
L2, n (%)3 (7.5)
L3, n (%)19 (47.5)
Behaviour
B1, n (%)13 (32.5)
B2, n (%)16 (40.0)
B3, n (%)11 (27.5)
Perianal lesions, n (%)7 (17.5)
Anti-TNF-naïve patients, n (%)24 (60.0)
Type of anti-TNF
Infliximab, n (%)16 (40.0)
Adalimumab, n (%)24 (60.0)
Concomitant medications
Immunosuppressive therapies, n (%)21 (52.5)
Steroids, n (%)7 (17.5)
Faecal calprotectin level at baseline, median (IQR) (µg/g)1010.5 (357.8-1800.0)
CRP level at baseline, median (IQR) (mg/L)13.2 (5.2-25.9)
Table 2 Performances of Crohn’s disease activity index, C-reactive protein, and faecal calprotectin after 12 wk of anti-tumor necrosis factor to predict steroids-free remission at week 52
EndpointsSensitivitySpecificityPPVNPVLR+LR-Accuracy
CDAI < 15084.6% (56.3-96.6)55.6% (37.3-72.4)47.8% (27.4-68.2)88.2% (72.9-100.0)1.904 (1.177-3.081)0.277 (0.074-1.035)60.5% (50.2-79.8)
CRP ≤ 2.9 mg/L92.3% (64.2-100.0)74.1% (55.0-86.9)63.2% (41.5-84.8)95.2% (86.1-100.0)3.560 (1.846-6.865)0.104 (0.016-0.692)80.0% (67.6-92.4)
CDAI < 150 and CRP ≤ 2.9 mg/L76.9% (48.9-92.2)85.2% (66.7-94.6)71.4% (47.8-95.1)88.5% (76.2-100.0)5.192 (2.004-13.456)0.271 (0.099-0.740)82.5% (70.7-94.3)
Fcal < 300 µg/g84.6% (56.3-96.6)77.8% (58.8-89.6)64.7% (42.0-87.4)91.3% (79.8-100%)3.808 (1.812-8.003)0.198 (0.054-0.719)80.0% (67.6-92.4)
Fcal improvement76.9% (48.9-92.2)92.6% (75.3-98.9)83.3% (62.2-100.0)89.3% (77.8-100.0)10.385 (2.648-40.721)0.249 (0.092-0.676)87.5% (77.3-97.7)
CDAI < 150 and Fcal improvement69.2% (42.0-87.4)96.3% (79.9-100.0)90.0% (71.4-100.0)86.7% (74.5-98.8)18.692 (2.640-132.328)0.320 (0.141-0.725)87.5% (77.3-97.7)
CDAI < 150 and CRP ≤ 2.9 mg/L and Fcal improvement69.2% (42.0-87.4)100.0% (84.9-100.0)100.0% (100.0-100.0)87.1% (75.3-98.9)NA0.308 (0.136-0.695)90.0% (80.7-99.3)